This position statement is based on the cur-rent evidence available on the safety and benefits of continous subcutaneous insulin pump therapy (CSII) in diabetes mellitus with an emphasis on the effects of CSII on glycemic control, hypoglycaemia rates, occur-ance of ketoacidosis, quality of life and the use of insu-lin pump therapy in pregnancy. The current article rep-resents the recommendations of the Austrian Diabetes Association for the clinical praxis of insulin pump treat-ment in children and adults.